Zydus announces Phase I trials of ZYIL1, oral small molecule NLRP3 inflammasome inhibitor EP News Bureau Dec 7, 2020 NLRP3 inflammasomes lead to the onset and development of diseases like ARDS, auto-immune diseases, inflammatory diseases, CVDs,…
